Published in Respir Res on April 16, 2013
Re-administration of gefitinib following diffuse interstitial lung disease in a patient with advanced lung adenocarcinoma: A case report and review of the literature. Oncol Lett (2015) 0.76
Efficacy of N-Acetylcysteine in Idiopathic Pulmonary Fibrosis: A Systematic Review and Meta-Analysis. Medicine (Baltimore) (2016) 0.76
Experimentation with aerosol bonsetan, pirfenidone, treprostinil and sidenafil. J Thorac Dis (2014) 0.75
End-of-life care of patients with idiopathic pulmonary fibrosis. BMC Palliat Care (2016) 0.75
Promising new treatment targets in patients with fibrosing lung disorders. World J Clin Cases (2014) 0.75
An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med (2011) 22.39
American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med (2000) 12.71
High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med (2005) 7.20
Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med (2012) 6.51
A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. N Engl J Med (2004) 6.02
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet (2011) 5.94
Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2005) 5.83
An official ATS statement: grading the quality of evidence and strength of recommendations in ATS guidelines and recommendations. Am J Respir Crit Care Med (2006) 5.29
A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2012) 4.81
Grading strength of recommendations and quality of evidence in clinical guidelines: report from an american college of chest physicians task force. Chest (2006) 4.77
Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J (2009) 4.63
Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial. Lancet (2009) 3.21
Anticoagulant therapy for idiopathic pulmonary fibrosis. Chest (2005) 3.02
Idiopathic pulmonary fibrosis: predicting response to therapy and survival. Am J Respir Crit Care Med (1998) 2.43
Non-steroid agents for idiopathic pulmonary fibrosis. Cochrane Database Syst Rev (2010) 1.66
An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med (2011) 22.39
An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med (2013) 6.82
An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline. Am J Respir Crit Care Med (2015) 6.03
Use in routine clinical practice of two commercial blood tests for diagnosis of infection with Mycobacterium tuberculosis: a prospective study. Lancet (2006) 5.19
Routine hospital use of a new commercial whole blood interferon-gamma assay for the diagnosis of tuberculosis infection. Am J Respir Crit Care Med (2005) 4.06
Prevalence and prognosis of unclassifiable interstitial lung disease. Eur Respir J (2012) 2.57
Sarcoidosis: challenging diagnostic aspects of an old disease. Am J Med (2012) 2.10
Non-steroid agents for idiopathic pulmonary fibrosis. Cochrane Database Syst Rev (2010) 1.66
Hot of the breath: mortality as a primary end-point in IPF treatment trials: the best is the enemy of the good. Thorax (2012) 1.65
Bronchoalveolar lavage enzyme-linked immunospot for a rapid diagnosis of tuberculosis: a Tuberculosis Network European Trialsgroup study. Am J Respir Crit Care Med (2009) 1.54
Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial. Ann Intern Med (2013) 1.51
A multicentre evaluation of the accuracy and performance of IP-10 for the diagnosis of infection with M. tuberculosis. Tuberculosis (Edinb) (2011) 1.34
Idiopathic pulmonary fibrosis: lung function is a clinically meaningful endpoint for phase III trials. Am J Respir Crit Care Med (2012) 1.26
Performance of commercial blood tests for the diagnosis of latent tuberculosis infection in children and adolescents. Pediatrics (2009) 1.14
Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials. Respir Res (2013) 1.10
Neglected evidence in idiopathic pulmonary fibrosis and the importance of early diagnosis and treatment. Eur Respir Rev (2014) 1.10
Interferon gamma assays for tuberculosis. Lancet Infect Dis (2005) 1.08
Bronchopulmonary actinomycosis associated with hiatal hernia. Mayo Clin Proc (2009) 0.98
Idiopathic pulmonary fibrosis: current and future treatment options. Am J Respir Med (2002) 0.96
Emerging drugs for idiopathic pulmonary fibrosis. Expert Opin Emerg Drugs (2011) 0.94
Prevalence and clinical significance of circulating autoantibodies in idiopathic pulmonary fibrosis. Respir Med (2012) 0.94
MDR1 C3435T genetic polymorphism does not influence the response to antiretroviral therapy in drug-naive HIV-positive patients. AIDS (2003) 0.90
The big clinical trials in idiopathic pulmonary fibrosis. Curr Opin Pulm Med (2012) 0.90
Lung cancer in scleroderma: results from an Italian rheumatologic center and review of the literature. Autoimmun Rev (2012) 0.89
Idiopathic pulmonary fibrosis: diagnostic pitfalls and therapeutic challenges. Multidiscip Respir Med (2012) 0.87
Room size is the major determinant for tuberculin conversion in health care workers exposed to a multidrug-resistant tuberculosis patient. Int Arch Occup Environ Health (2006) 0.87
Idiopathic pulmonary fibrosis: CT and risk of death. Radiology (2014) 0.87
The Italian register for diffuse infiltrative lung disorders (RIPID): a four-year report. Sarcoidosis Vasc Diffuse Lung Dis (2005) 0.86
The role of biomarkers in low respiratory tract infections. Eur J Intern Med (2012) 0.85
Idiopathic pulmonary fibrosis: current challenges and future perspectives. Eur Respir Rev (2013) 0.85
Fibulin-1 predicts disease progression in patients with idiopathic pulmonary fibrosis. Chest (2014) 0.84
Impact of a T cell-based blood test for tuberculosis infection on clinical decision-making in routine practice. J Infect (2006) 0.83
Pirfenidone. Nat Rev Drug Discov (2011) 0.83
Environmental triggers and susceptibility factors in idiopathic granulomatous diseases. Semin Respir Crit Care Med (2009) 0.83
Exploring the immune response against Mycobacterium tuberculosis for a better diagnosis of the infection. Arch Immunol Ther Exp (Warsz) (2009) 0.82
Treatments for idiopathic pulmonary fibrosis. N Engl J Med (2014) 0.82
Atypical lipomatous tumour (lipoma-like well-differentiated liposarcoma) arising in a pulmonary hamartoma and clinically presenting with pneumothorax. Lung Cancer (2003) 0.81
End of an ERA: lessons from negative clinical trials in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2011) 0.81
Management of idiopathic pulmonary fibrosis. Clin Chest Med (2011) 0.80
Steroid and/or other immunosuppressive therapies in idiopathic interstitial pneumonias: have they still a role? Sarcoidosis Vasc Diffuse Lung Dis (2005) 0.79
Efficacy of hormonal suppression in a patient with chyluria due to lymphangioleiomyomatosis. Multidiscip Respir Med (2011) 0.78
Idiopathic pulmonary fibrosis: recent trials and current drug therapy. Respiration (2013) 0.78
Acute exacerbations of chronic obstructive pulmonary disease: are antibiotics needed? Am J Respir Crit Care Med (2010) 0.77
A decade of interferon-γ release assays: quest for the holy grail to diagnose latent infection with mycobacterium tuberculosis? Am J Respir Crit Care Med (2011) 0.76
Genetic testing in diffuse parenchymal lung disease. Orphanet J Rare Dis (2012) 0.75
The reply. Am J Med (2013) 0.75
Identifying patients with idiopathic pulmonary fibrosis: quality or quantity? Am J Respir Crit Care Med (2007) 0.75
Viruses and acute exacerbations of idiopathic pulmonary fibrosis: rest in peace? Am J Respir Crit Care Med (2011) 0.75
Diagnosing latent tuberculosis infection: guess who's coming to dinner? Am J Respir Crit Care Med (2009) 0.75
Interferon gamma-1b for pulmonary fibrosis. N Engl J Med (2004) 0.75
A culture-proven case of community-acquired legionella pneumonia apparently classified as nosocomial: diagnostic and public health implications. Case Rep Med (2013) 0.75
Air pollution and acute exacerbations of idiopathic pulmonary fibrosis: back to miasma? Eur Respir J (2014) 0.75
To BAL or not to BAL: is this a problem in diagnosing IPF? Am J Respir Crit Care Med (2009) 0.75
Idiopathic Pulmonary Fibrosis: Molecular Endotypes of Fibrosis Stratifying Existing and Emerging Therapies. Respiration (2017) 0.75
Amyotrophic lateral sclerosis and sarcoidosis: a difficult differential diagnosis. Amyotroph Lateral Scler (2010) 0.75
Interstitial lung diseases. Preface. Clin Chest Med (2012) 0.75
Unexpected identification of bilateral masses in an asymptomatic heavy smoker. Thorax (2010) 0.75
Treating idiopathic pulmonary fibrosis: current opportunities and future challenges. Clin Respir J (2012) 0.75
[New tools for a better diagnosis of latent tuberculosis infection]. Recenti Prog Med (2006) 0.75
Do all patients with idiopathic pulmonary fibrosis warrant a trial of therapeutic intervention? A pro-con perspective. Respirology (2015) 0.75